Clin2
NCT03957902Possibly a fitRecruiting

Aspirin blood markers to guide prevention after colon cancer

Colorectal Cancer

Treatments studied

Part of Cancer, Digestive system clinical trials.

This Phase 2 trial studies how aspirin affects specific “biomarkers” (measurable body signals) in people newly diagnosed with colon or rectal cancer. The goal is to see whether aspirin-related changes can help design more personalized prevention treatment plans.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 79 years
Study type
Interventional

Who can take part

  • You are between 18 and under 80 years old
  • Your colon or rectal cancer diagnosis was confirmed very recently (within 48 hours) by scope/endoscopy and pathology
  • You have no known bleeding disorder and your blood clotting and basic blood tests are within normal ranges
  • You do NOT have an allergy to aspirin (ASA) or other NSAIDs (pain medicines like ibuprofen/naproxen)
  • In the last 15 days you have not taken aspirin/NSAIDs/antiplatelet medicines/corticosteroids/misoprostol, and you do not need them during the study
  • You are not pregnant or breastfeeding, and you are not actively smoking; also no history of drug or alcohol abuse

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05411718Recruiting· Phase 2
Aspirin or naproxen to prevent cancer in Lynch syndrome

This trial tests whether daily aspirin or naproxen can “intercept” (stop) cancer from starting or coming back in people with Lynch syndrome who are currently cancer-free. Participants are randomly assigned to one of the two drugs, and neither the participant nor the team knows which one you’re taking.

Houston, Texas
NCT04214990Recruiting· Phase 3
Aspirin after early stomach precancer or early cancer removal

This trial tests whether taking aspirin after endoscopic removal of an early stomach condition can lower the chance of the cancer coming back or progressing. You may be considered if your early stomach findings were fully removed and you’re able to avoid certain medications that raise bleeding risk.

Busan
NCT05637567Not yet recruiting· Phase 2
Aspirin before pancreatic surgery to improve blood-clot outcomes

This trial tests whether taking low-dose aspirin around the time of pancreatic head surgery (a Whipple-type operation) can improve outcomes by affecting platelet-driven clotting. You may be eligible if you have a tumor that can be surgically removed and your doctors plan a specific type of pancreatic operation.

NCT03919461Recruiting· Phase 2
Preventing colon and rectal cancer spread after surgery

This Phase 2 study tests medicines given around the time of colon or rectal cancer surgery to help lower the chance the cancer will later spread to other parts of the body. If you are planned for curative (potentially curable) surgery and have no signs of spread yet, the trial may help prevent future metastases.

Afula
NCT07524335Not yet recruiting· Phase 3
Aspirin for early coronary artery disease without symptoms

This trial tests whether taking aspirin can help people who have early signs of coronary artery disease (buildup in heart arteries) but have never had a heart attack or stroke. The goal is to see if aspirin prevents future heart problems in these patients.

Montreal, Quebec
NCT05633810Recruiting· Phase 3
Testing colchicine plus coated aspirin to prevent heart events

This Phase 3 study tests whether colchicine and a special type of aspirin can lower the risk of future heart attacks, strokes, or other major heart problems in people with type 2 diabetes who have not had a prior heart event. It aims to reduce cardiovascular risk using medicines that may calm inflammation and protect blood vessels.

Bentley, Western Australia

Hear when a new Colorectal cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.